Longitudinal immune dynamics of mild COVID-19 define signatures of recovery and persistence

A Talla, SV Vasaikar, MP Lemos, Z Moodie… - BioRxiv, 2021 - biorxiv.org
SARS-CoV-2 has infected over 160 million and caused more than 3 million deaths to date.
Most individuals (> 80%) have mild symptoms and recover in the outpatient setting, but …

[HTML][HTML] An overview of the conventional and novel methods employed for SARS-CoV-2 neutralizing antibody measurement

VPC Rocha, HC Quadros, AMS Fernandes… - Viruses, 2023 - mdpi.com
SARS-CoV-2 is the etiological agent of the coronavirus disease-19 (COVID-19) and is
responsible for the pandemic that started in 2020. The virus enters the host cell through the …

[HTML][HTML] Vaccination with SARS-CoV-2 spike protein and AS03 adjuvant induces rapid anamnestic antibodies in the lung and protects against virus challenge in …

JR Francica, BJ Flynn, KE Foulds, AT Noe, AP Werner… - BioRxiv, 2021 - ncbi.nlm.nih.gov
Adjuvanted soluble protein vaccines have been used extensively in humans for protection
against various viral infections based on their robust induction of antibody responses. Here …

Humoral responses against SARS-CoV-2 and variants of concern after mRNA vaccines in patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia

A Chang, A Akhtar, SL Linderman, L Lai… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE Patients with non-Hodgkin lymphoma including chronic lymphocytic leukemia
(NHL/CLL) are at higher risk of severe SARS-CoV-2 infection. We investigated vaccine …

[HTML][HTML] An mRNA vaccine encoding the SARS-CoV-2 receptor-binding domain protects mice from various Omicron variants

R Uraki, M Imai, M Ito, S Yamayoshi, M Kiso, N Jounai… - npj Vaccines, 2024 - nature.com
Here, we assessed the efficacy of a lipid nanoparticle-based mRNA vaccine candidate
encoding the receptor-binding domain (LNP-mRNA-RBD) in mice. Mice immunized with …

[HTML][HTML] SARS-CoV-2 shedding and evolution in immunocompromised hosts during the Omicron period: a multicenter prospective analysis

Z Raglow, D Surie, JD Chappell, Y Zhu, ET Martin… - medRxiv, 2023 - ncbi.nlm.nih.gov
Background: Prolonged SARS-CoV-2 infections in immunocompromised hosts may predict
or source the emergence of highly mutated variants. The types of immunosuppression …

Reduced binding and neutralization of infection-and vaccine-induced antibodies to the B. 1.351 (South African) SARS-CoV-2 variant

VV Edara, C Norwood, K Floyd, L Lai… - BioRxiv, 2021 - biorxiv.org
The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising
concerns about the efficacy of infection-or vaccine-induced antibodies to neutralize these …

The serological sciences network (SeroNet) for COVID-19: depth and breadth of serology assays and plans for assay harmonization

AB Karger, JD Brien, JM Christen, S Dhakal, TJ Kemp… - MSphere, 2022 - Am Soc Microbiol
ABSTRACT In October 2020, the National Cancer Institute (NCI) Serological Sciences
Network (SeroNet) was established to study the immune response to COVID-19, and “to …

An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination

JM Carreño, A Raskin, G Singh, J Tcheou… - Science Translational …, 2023 - science.org
NDV-HXP-S is a recombinant Newcastle disease virus–based vaccine against SARS-CoV-
2, which expresses an optimized (HexaPro) spike protein on its surface. The vaccine can be …

[HTML][HTML] Neutralizing antibody: a savior in the Covid-19 disease

SL Gupta, RK Jaiswal - Molecular biology reports, 2022 - Springer
Coronavirus outbreak was declared a pandemic by World Health Organization (WHO) in
March 2020. The pandemic has led to a devastating loss of life. It has shown us how …